RxDoctor Payments Data

Eliza Sangmuah, MD

Internal Medicine · Matthews, NCNPI 1215931894

Payments from drug & device makers

$8,035in general payments, 2019–2025

Across 445 payments — averaging $18.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$829
  • Lilly USA, LLC$764
  • Amgen$615
  • AbbVie$602
  • Pfizer$397
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$8,029100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,035 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$81,744
Medicare patients
288
Services billed
984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$52,915
JardianceEmpagliflozin39$31,995
EliquisApixaban30$28,995
MounjaroTirzepatide23$24,705
Tresiba Flextouch U-200Insulin Degludec18$15,348
JanuviaSitagliptin Phosphate14$14,902
TrulicityDulaglutide14$13,465
Janumet XrSitagliptin Phos/Metformin Hcl11$12,348
MyrbetriqMirabegron13$11,221
Repatha SureclickEvolocumab13$10,608
RestasisCyclosporine12$8,073
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$8,036
FarxigaDapagliflozin Propanediol13$7,040
Breo ElliptaFluticasone/Vilanterol11$5,921
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf40$2,795

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,050$52,91533 claims
Lilly USA, LLCMounjaro, Trulicity$764$38,17037 claims
Boehringer IngelheimJardiance$396$31,99539 claims
PfizerEliquis$397$28,99530 claims
MerckJanuvia, Janumet Xr$87$27,25025 claims
GSKTrelegy Ellipta, Breo Ellipta$142$13,95723 claims
Astellas Pharma US IncMyrbetriq$101$11,22113 claims
AbbVieRestasis, Armour Thyroid$602$8,62828 claims
AstraZenecaFarxiga$829$7,04013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Matthews

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →